Therapeutic Usages of Oxygen Radical Scavengers in Human Diseases: Myths and Realities

References

• Greenwald R. A. Introduction to session on clinical and therapeutic aspects. Oxy Radicals and Their Scavengers Systems, Vol. II. Cellulur and Medical Aspects., R. A. Greenwald, G. Cohen. Elsevier, New York 1983; 239–241
   Google Scholar
• Cross C. Oxygen radicals and human disease. Annals Internal Medicine 1987; 107: 526–545
   PubMed Web of Science ®Google Scholar
• Grecnwald R. A. Therapeutic benefits of oxygen rddical scavenger Ireatments remain un-proven. Journal of Free Radical Biology in Medicine 1985; 1: 173–177
   PubMedGoogle Scholar
• Flohe L. Superoxide dismutase for therdpeutic use: clinical experience. dead ends, and hopes. Molecular Cellular Biochemistry 1988; 84: 123–131
   PubMed Web of Science ®Google Scholar
• Giri S. N., Misra H. P. Fate of supcroxidc dismutase in mice following oral routc of administration. Molecular Biology 1984; 62: 285–289
   Google Scholar
• Mossman B. T., Marsh J., Hardwick D., et al. Approaches to prevention of asbestos-induced lung disease using polyethylene glycol (PEG)-conjugated catalase. Journal of Free Radical Biology in Medicine 1986; 2: 335–338
   PubMedGoogle Scholar
• Beckman J. S., Minor R. L., White C. W., et al. Superoxide dismutase and catalase conjugated to polyethylene glycol increases endothelial enzyme activity and oxidant resistance. Journal of Biological Chemistry 1988; 263: 6884–6892
   PubMed Web of Science ®Google Scholar
• Schwalwijk J., van den Berg W. B., van de Putte L., et al. Cationization of catalase. peroxidasc. and superoxide dismutasc. Journal of Clinical Investigation 1985; 76: 198–205
   PubMedGoogle Scholar
• Hallewell R. A., Laria I., Tabrizi A., et al. Genetically engineered polymers of human CuZn superoxide dismutase. Journal of Biological Chemistry 1989; 264: 5260–5268
   PubMedGoogle Scholar
• Oda T., Akaike T., Hamamoto T., et al. Oxygen radicals in influenza-induced pathogenesis and treatment with pyran polymer conjugated SOD. Science 1989; 244: 974–976
   PubMed Web of Science ®Google Scholar
• Rosenfeld W., Evans H., Jhaveri R., et al. Safety and plasma concentrations of bovine superoxide dismutase administered to human premature infants. Dev. Pharmacol. Ther. 1982; 5: 151–161
   PubMedGoogle Scholar
• McLlwain H., Silverfield J. C., Cheatum D. E., Poiley J., Taborn J., Ignanak T., Multz C. V. Intraarticular orgotein in osteoarthritis of the knee: a placebotontrolled efficacy, safety, and dosage comparison. American Journal of Medicine 1989; 87: 295–300
   PubMedGoogle Scholar
• Rosenfeld W., Evans H., Conccpcion L., et al. Prevention of bronchopulmonary dysplasia by administration of bovine superoxide dismutase in preterm infants with respiratory distress syndrome. Journal of Pediatrics 1984; 105: 781–785
   PubMed Web of Science ®Google Scholar
• Catron P. W., Thomas L. B., McDermott J. J., et al. Failure of heparin, superoxide dismutasc, and catalase to protect against decompression sickness. Undersea Biomedical Research 1987; 14: 319–330
   PubMedGoogle Scholar
• Harley J. B., Grinspan S., Root R. K. Paraquat suicide in a young woman: results of therapy directed against the superoxide radical. Yale Journal of Biological Medicine 1977; 50: 481–488
   PubMed Web of Science ®Google Scholar
• Block E. R. Effect of superoxide dismutase and succinate on the development of hyperbaric oxygen toxicity. Aviation, Space. Environmental Medicine. 1977; XX–648, 645
   Google Scholar
• Hilton J. G., Brown G. L., Proctor P. H. Effects of superoxide dismutase and catalase on central nervous system toxicity of hyperbaric oxygen. Toxicology Applied Pharmacology 1980; 53: 50–53
   PubMed Web of Science ®Google Scholar
• Yusa T., Crapo J. D., Freeman B. A. Liposome mediated augmentation of brain SOD and catalasc inhibits CNS O2 toxicity. Journal of the American Physiology Society 1984; 57: 1674–1681
   Google Scholar
• Chan P. H., Longar S., Fishman R. A. Protective effects of liposome entrapped superoxide dismutase on posttraumatic brain edema. Annals Neurology 1987; 21: 540–547
   PubMed Web of Science ®Google Scholar
• Cuevas P., Carceller-Benito F., Reimers D. Administration of bovine superoxide dismutase prevents sequelae of spinal cord ischemia in the rabbit. Anatomy Embryology 1989; 179: 251–255
   PubMedGoogle Scholar
• Put T. R. The favorable effect of adding a catalase to the treatment of syndromes due to intervertebral disk degenerations. Arzneimittel Forschung (Drug Research) 1975; 25: 951–956
   PubMedGoogle Scholar
• Lund-Olesen K. Intrathelcal orgotein. International Clinical Pharmacology Research 1985; 1: 59–62
   Google Scholar
• Stern L. Z., Ringel S. P., Ziter F. A., et al. Drug trial of superoxide dismutase in Duchenne's muscular dystrophy. Archives in Neurology 1982; 39: 342–346
   PubMedGoogle Scholar
• Sagi A., Ferder M., Levens D., et al. Improved survival of island flaps after prolonged ischemia by perfusion with superoxide dismutase. Plastic Reconstructive Surgery 1986; 77: 639–641
   PubMed Web of Science ®Google Scholar
• Bitterman H., Aoki N., Lefer A. M. Anti-shock effects of human superoxide dismutase in splanchnic artery occlusion (SAO) shock. Proceedings of the Society of Experimental Biology and Medicine 1988; 168: 265–271
   Google Scholar
• Couinaud C., Goddio A. S., Elkoubi P. La superoxydedismutax dans Ies phenomenes ischemiques chez I'homme. Chirurgie 1987; 113: 897–901
   PubMedGoogle Scholar
• Yoshikawa T., Murakami M., Yoshida N., et al. Effects of superoxide dismutase and catalase on disseminated intravascular coagulation in rats. Throm Haemostasis (Stuttgart) 1983; 50: 869–872
   PubMed Web of Science ®Google Scholar
• Emerit J., Loeper J., Chomette G. Superoxide dismutase in the treatment of post-radioth-erapeutic necrosis and of Crohn's disease. Bull European Physioputhological Resp 1981; 17%(suppl)287
   PubMedGoogle Scholar
• Pascu O., Dejica D. Oxygen free radicals and duodenal ulcer pain: preliminary data. Rev Roum Med -. Med Int. 1987; 25: 81–84
   Google Scholar
• Beckmann R., Flohe L. The pathogenic role of superoxide radicals in inflammation: efficacy of exogenous superoxide dismutase. Bull European Physiopathological Resp. 1981; 17%(suppl)275–285
   PubMedGoogle Scholar
• Reuss K., Carl P. Behandlung des Ulcus simplex vesicae und der ulzerierended radiogene Zystitis mit Superoxiddismutase. Urologie 1983; 22: 290–293
   Google Scholar
• Schneider H-J., Rugendoroff E. W., Rohrborn C. Pathogenesis, diagnosis and therapy of induratio penis plastica (IPP). International Urology Nephrology 1985; 17: 235–244
   PubMedGoogle Scholar
• Verges J., Chateau A. Nouveau traitement de la maladie de la Peyronie: la superoxyde dismutase par ionisations. Annals in Urology 1985; 22: 143–144
   Google Scholar
• Playter R. F., Ellett E. W., Brown C. D. Superoxide dismutase drug study. Journal of the American Veterinary Medical Associotion 1980; 176: 586–587
   PubMedGoogle Scholar
• Brainard J., Hanna C., Petursson G. Evaluation of superoxide dismutase (Orgotein) in medical treatment of canine cataract. Archives in Ophthalmology 1982; 100: 1832–1834
   PubMedGoogle Scholar
• Nirankari V. S., Varma S., Lakhanpal V., et al. Superoxide radical scavenging agents in treatment of alkali bums. Archives in Ophthalmology 1981; 99: 886–887
   PubMedGoogle Scholar
• Guy J., Ellis A., Hope G. M., et al. Influence of anti-oxidant enzymes in reduction of optic disc edema in experimental optic neuritis. Journal of Free Radical in Biological Medicine 1986; 2: 349–357
   PubMedGoogle Scholar
• Rao N. A., Calandra A. J., Sevanian A., et al. Modulation of lens-induced uveitis by superoxide dismutase. Ophthalmic Research 1988; 18: 41–46
   Google Scholar
• Somiya K., Niwa Y., Fukami S., et al. Effect of liposomal encapsulated superoxide dismutase on patients with Kawasaki disease. Kawasaki Disease: Progress in Clinical and Biological Research. Alan R. Liss Inc. 1987; 573–575
   Google Scholar
• Emerit J., Jeny C., Emerit I., et al. Etude preliminaire de I'effet therapeutique de la supcroxyde dismutax dans sept cas de maladie de Behat. Comptes Rendus de I'Academie des Sciences de Paris 1988; 302: 243–246
   Google Scholar
• Petkau A. Scientific basis for the clinical use of superoxide dismutase. Cancer Treatment Reviews 1986; 13: 17–44
   PubMed Web of Science ®Google Scholar
• Oberley L. W., Leuthauser S. W., Pasternack R. F., et al. Anticancer activity of metal compounds with superoxide dismutase activity. Agents Actions 1984; 15: 535–538
   PubMedGoogle Scholar